Abstract
Introduction
Nicotinic acid (niacin), a water-soluble vitamin, has been used to regulate abnormalities in plasma lipid metabolism and in the treatment of atherosclerotic cardiovascular disease. 1 2 3 4 5 6 7 In pharmacological doses, niacin reduces total plasma cholesterol, triglyceride, VLDL, and LDL concentrations. 8 It is the most potent clinically used agent that increases circulating HDL cholesterol and apo A-I, the major protein of HDL. 8 9 10 11 12 Niacin in combination with bile acid binding resin also significantly decreases small, dense LDL particles in patients with low LDL. 13 Additionally, niacin treatment decreases plasma levels of lipoprotein(a) in hyperlipidemic patients. 14 Since HDL has been shown to inhibit LDL oxidation, promote reverse cholesterol transport, and be profibrinolytic, low levels of HDL in patients with coronary artery disease may result in increased cardiovascular events. 15 16 17 Furthermore, long-term follow-up of patients in the Coronary Drug Project, 18 coronary arteriographic studies including the Cholesterol Lowering Atherosclerosis Study, 19 and the Familial Atherosclerosis Treatment Study 20 indicated that treatment with niacin significantly reduced total mortality, reduced coronary events, and retarded progression and even induced regression of coronary atherosclerosis in some patients.
Although niacin has been widely used to increase plasma HDL levels, the mechanism by which niacin exerts its action is not clearly understood. On the basis of plasma kinetic studies, it was suggested that the rise in plasma apoA-I in patients treated with niacin was the result of decreased fractional clearance rates rather than alterations in synthetic rates. 16 21 These studies led us to examine in greater detail the direct effect of niacin on hepatic production and removal of HDL and its components. Because the liver is the major organ for the synthesis and removal of HDL in humans, we used Hep G2 cells, a human hepatoblastoma cell line that has been shown to be a useful model for studying hepatic lipoprotein metabolism 23 24 and has helped in gaining concepts about mechanisms of action of hormones and drugs on HDL at the cellular level in contrast to in vivo kinetic studies. In this investigation, we examined the effect of niacin on cultured Hep G2 cells on: (1) synthesis and secretion of apoA-I; (2) steady state mRNA expression for apoA-I; (3) uptake of radiolabeled HDL protein, specifically HDL apoA-I, and HDL CEs;
and (4) properties of secreted material to functionally efflux cellular cholesterol. This study demonstrated a selective decrease in hepatic HDL protein and apoA-I uptake by niacin. Part of this work has been presented in abstract form. 25 
Methods
Tissue culture materials, medium, FBA, pure human apoA-I, and niacin were obtained from 
HDL Isolation
Blood samples were collected from fasting healthy human volunteers, and serum was isolated by centrifugation and pooled for lipoprotein isolation. HDL was isolated by sequential density ultracentrifugation at a final density of 1.210 g/mL. 26 The purity of lipoprotein was monitored by agarose gel electrophoresis, and protein content was measured by the method of Lowry et al 27 using bovine serum albumin as a standard.
Separation of HDL Particles
Serum from fasting (>12 hours) healthy volunteers was collected and LPAI (ie, all HDL particles bearing apoA-I, including apoA-II) particles were isolated by immunoaffinity column chromatography. 28 In brief, affinity columns specific for apoA-I were prepared by coupling polyclonal antibodies for human apoA-I to CNBr-activated Sepharose 4B (Pharmacia) according to the manufacturer's procedure. Aliquots of serum were loaded onto the apoA-I affinity column and incubated at 4°C for 16 to 18 hours to allow binding of HDL particles to specific antibody. The affinity column was then washed with 0.5 mol/L NaCl and retained apoA-I-containing HDL particles were eluted with 3 mol/L NaSCN, pH 6.0. LPAI HDL was tested by SDS-polyacrylamide gel electrophoresis for purity.
Cell Culture
Hep G2 cells were grown in T-75 flasks with 15 mL of high-glucose DMEM containing 10% FBS, 1%
glutamine-penicillin-streptomycin, and 1% fungizone. Cells were grown in a humidified incubator at 37°C in an atmosphere of 5% CO 2 and 95% air. Subcultures were made from confluent stock cultures by trypsinization with PBS containing 0.5 mmol/L ethylene diamine tetraacetic acid. Human fibroblast cells were cultured in T-75 flasks with 15 mL of DMEM at 37°C in a humidified incubator with 5% CO 2 . Subcultures were made as described above and passages between 18 and 20 were used for various experiments. The cells were plated in 60-mm culture petri dishes at a concentration of 4x10 6 cells per dish in 4 mL DMEM and grown for 3 to 4 days until they attained 75% to 80% confluence. The studies examining the dose response of niacin on culture medium concentration of apoA-I were performed by incubating Hep G2 cells with various amounts of niacin (0 to 3.0 mmol/L) at 37°C for 72 hours. At the termination of the incubation, culture medium from each flask were removed, and the cell monolayer was washed with PBS and collected for cellular protein measurement. A 50-µL sample of culture medium was assayed for apoA-I by an enzyme-linked immunoassay using a human apoA-I-specific monoclonal antibody (HB-22) developed and characterized in our laboratory. 29 The concentration of apoA-I was expressed as micrograms per milligram of cellular protein.
Studies on the

De Novo Synthesis of ApoA-I
Studies examining the effect of various doses of niacin on the de novo synthesis of apoA-I by Hep G2 cells were performed by measuring the incorporation of radiolabeled leucine into apoprotein secreted into the medium. Hep G2 2) was added at 0 to 3.0 mmol/L niacin. Cells were harvested 6 hours later, washed thoroughly, and digested with 1 mL of 1N NaOH. 34 Radioactivity was measured and expressed as counts per minute per milligram cellular protein.
The same method was used for the [ 3 H]CE of apoA-I-containing HDL particles isolated by immunoaffinity (ie, LPAI).
Measurement of Cholesterol Efflux
Experimental protocols for these studies were exactly the same as described for medium accumulation of apoA-I.
After the incubation of Hep G2 cells with niacin, the medium was collected and used for cholesterol efflux
measurement. An aliquot of culture medium (5 mL) was concentrated to 1 mL by lyophilization and dialyzed against DMEM to remove excess salt present in the concentrated samples. The ability of these concentrated samples to efflux free cholesterol was measured by a previously described modified procedure of Fielding and Fielding 35 
Northern Blot Analysis
Experimental protocols for Northern blot analysis were exactly the same as described in apo A-I accumulation studies. Total RNA was isolated from Hep G2 cells using the protocol of Chomczynski and Sacchi. 39 Twenty micrograms of total RNA was loaded into individual wells of a 1.0% agarose gel containing formaldehyde, and electrophoresis was performed. 40 The RNA from the gel was transferred onto MSI nylon membranes, UV cross-linked, and the membranes were hybridized overnight with the 32 P-labeled cDNA probe for human apoA-I mRNA. The membranes were washed three times for 30 minutes:
first in 2x SSC with 0.1% SDS at room temperature, second in 0.2x SSC with 0.1% SDS at room temperature, and third in 0.2x SSC with 0.1% SDS at 50°C. Autoradiography was performed by exposing the blots to X-ray films with intensifying screens at -70°C. Blots were then rehybridized with 32 P-labeled human GAPDH (Clontech) cDNA probe as an internal control to assess RNA quantity and integrity. Quantification of mRNA signals was performed by densitometric scanning of autoradiographic bands and normalized with GAPDH mRNA signals, using the LKB laser densitometer (Pharmacia Biotech).
Statistical Analysis
Mean data present average value for each set of experiments done in triplicate. Statistical significance was calculated by using the Student's t test, and P<.05 was considered significant.
Results
The preincubation of Hep G2 cells with varying concentrations of niacin (0 to 3.0 mmol/L) for 72
hours at 37°C resulted in a dose-dependent increase in apoA-I mass in the culture medium ( (Table 1 ) .
Additional experiments were performed to confirm the de novo apoA-I synthesis data by using Table 2 ) .
Northern blot analysis was performed to examine the effect of niacin on apoA-I gene expression by Hep G2 cells.
Incubation of varying amounts of niacin (0 to 3.0 mmol/L) with Hep G2 cells had no effect on the steady state apoA-I mRNA levels compared with control level (Fig 2 ) . Quantitative analysis performed by densitometric induced by enhanced apoA-I accumulated in niacin-treated cell medium rather than equilibration of free cholesterol between cells and medium. property, apoA-I-containing HDL particles were isolated by immunoaffinity columns. The CE component of HDL uptake was assessed by using the same method as described above. Hep G2 cells preincubated with niacin did not alter the uptake of [ 3 H]CE HDL particles (Table 3 ) . 
View larger version (64K): [in this window] [in a new window]
View larger version
Discussion
On the basis of numerous epidemiological and case-controlled studies, it is generally accepted that an inverse correlation exists between the plasma concentrations of HDL and the severity of the development of atherosclerotic cardiovascular disease. 41 42 43 44 Although the mechanisms for this association are not clearly delineated, the cardioprotective effects of HDL have been largely attributed to the ability of apoA-I, the major protein of HDL, to initiate cholesterol efflux and thereby facilitate the removal of excess cholesterol from peripheral tissues (including arteries) and its delivery to the liver for degradation through reverse cholesterol transport pathways. 35 45 In recent years, additional direct support for the antiatherogenic properties of HDL has been provided by studies demonstrating that the direct infusion of high doses of HDL to cholesterol-fed rabbits could regress atherosclerotic lesion formation in these animals 46 and that cholesterol-fed transgenic mice engineered to produce high concentrations of apoA-I failed to develop atherosclerotic lesions. 47 Using Hep G2 cells as an in vitro model, we and others have shown that gemfibrozil directly increased apoA-I synthesis without altering the uptake of apoA-I or HDL particles, an observation consistent with in vivo turnover studies previously reported by us indicating that gemfibrozil has a stimulatory effect on the transport rate of apoA-I without altering its fractional catabolic rate. 48 49 50 Taken together, these studies suggest that the in vitro Hep G2
cell model system may serve as an important cellular and molecular tool to determine the mechanisms of action of pharmacological agents and hormones. In this study, using Hep G2 cells as an in vitro model, we examined the effect of niacin on apoA-I synthesis and removal to delineate the hepatic cellular mechanism of niacin. on a putative hepatic HDL receptor and perhaps on the very recently described "docking" HDL receptor for selectively removing HDL CEs. 51 We suggest this hypothesis as a distinct possibility that requires examination;
however, it was beyond the scope of this investigation and remains a subject for future research.
In contrast to the effect of niacin on radiolabeled HDL protein or HDL apoA-I uptake, niacin did not alter the uptake 48 However, the novel observation as discussed in this report indicates that if the selective hepatic removal of cholesterol remains intact, decreased catabolism of HDL protein or HDL apoA-I would result in a greater mass of circulating functional HDL, which could facilitate reverse cholesterol transport.
In the above HDL-Hep G2 interaction studies, HDL was obtained by ultracentrifugation. It is possible that the selective CE uptake may be an artifact of the drastic ultracentrifugal force and high salt solutions affecting HDL during its preparation from plasma. To address this question, we assessed the effect of niacin on HDL protein versus HDL CE Hep G2 cell uptake on HDL isolated by immunoaffinity, which would presumably result in "native" HDL particles. The data obtained confirmed the earlier observation. Niacin decreased uptake of LPAI protein but did not affect LPAI CE uptake (Fig 7 and Table 3 ).
Our studies also show that accumulated apoA-I in Hep G2 cell culture medium in response to niacin treatment was functionally active in increasing cholesterol efflux from fibroblasts. These data indicate that niacin treatment may inhibit the removal of HDL apoA-I by Hep G2 cells, thus retaining excess apoA-I-containing HDL particles in the plasma that may ultimately retard atherosclerosis progression by augmenting reverse cholesterol transport pathway.
The increased cholesterol efflux mediated by culture medium incubated with radiolabeled cholesterol is explained by the retention and increased concentration of apoA-I-containing particles in the medium. Although detailed characterization of the medium HDL particle composition was not available, it is possible that the cholesterol efflux was mediated by nascent HDL and possibly pre-ß migrating HDL, which has been shown to effect increased cholesterol efflux. 55 The data also indicate that niacin did not alter the culture medium concentration of free cholesterol, nor did it alter [ 14 C]acetate incorporation into free cholesterol. Increased efflux was also observed at shorter time periods (4 hours) of incubation. Therefore, the measured increase in cholesterol efflux represents unidirectional flux.
Previous in vivo studies have shown that the treatment of patients with niacin markedly increased plasma HDL 2 :HDL 3 ratio. 16 56 Additionally, these studies have also indicated that the rise in plasma concentration of apoA-I in patients treated with niacin was primarily accomplished through a decrease in its fractional catabolic rate. 16 22 56 The observation made in Hep G2 cells regarding the effect of niacin on apoA-I removal is in line with in vivo HDL turnover studies in patients with hyperlipidemia, demonstrating that niacin treatment decreases the fractional catabolic rate of HDL but does not affect the HDL synthetic transport rate. 16 22 56 Previous investigators have suggested that the effects of niacin on the HDL subfraction distribution may be mediated via a net transfer of apoA-I from HDL 3 to HDL 2 . 22 56 Although these studies indicate the beneficial effects of niacin in raising the The in vitro observations in this study do not completely answer the question of whether niacin favorably affects reverse cholesterol transport in vivo and thereby retards clinically documented atherogenesis. However, these findings indicate a novel concept and prompt the need for further studies. For example, the niacin effect described here also needs to be confirmed in primary human hepatocytes and in perfused livers. At the in vivo level, turnover studies that simultaneously assess niacin's effect on kinetic parameters of HDL apoA-I versus HDL CE need to be conducted to validate the concept. It is recognized that the isolated cell culture system is not totally representative of the dynamically changing humoral milieu of the liver in vivo.
In summary, in this study, niacin selectively decreased hepatic removal of HDL protein and apoA-I without altering the removal of HDL CEs. Thus, it increased the efficiency of selective hepatic removal of CEs from HDL. Niacin had no effect on apoA-I de novo synthesis and steady state mRNA expression by Hep G2 cells. The data indicate a new and previously undescribed concept for increasing HDL levels and possibly reverse cholesterol transport.
Similar mechanisms may exist for other hormonal and pharmacological agents that alter HDL levels. 
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